Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipalolitovorelimab plus neoadjuvant chemotherapy in locally advanced cervical cancer
ChiCTR2500105737Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Jul 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ipalolitovorelimab in Cervical Cancer (CC), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Pathological Complete Response Rate (pCR). Planned start Jul 2025; status: not yet recruiting.
02
Drugs
ipalolitovorelimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500105737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105737.